# Technologies to Advance Precision Medicine for Reproductive Health and Infertility (R43, R44 Clinical Trial Optional)

Source: https://welltoldgrants.com/grants/rfa-hd-22-010-technologies-to-advance-precision-medicine-for-reproductive/  
Official notice: https://www.grants.gov/search-results-detail/332517

> National Institutes of Health offered grants to small businesses. It expected to make $1.5 million in total. Applications closed on July 29, 2021.

| Field | Value |
|---|---|
| Opportunity number | RFA-HD-22-010 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | July 29, 2021 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | $1.5 million |
| Cost sharing | not required |
| Assistance Listings | 93.865 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

## What the grant funds

The purpose of this funding opportunity announcement (FOA) is to encourage the small business community to collaborate with scientists and clinicians in the fields of female and male reproductive medicine, infertility, andrology/urology, and gynecology to develop, adapt and validate discoveries in genomics, epigenomics, metabolomics and biomarkers to the clinical diagnosis and treatment of women and men with infertility, and diseases and disorders that affect fertility. The ultimate goal is to advance the application of precision medicine to reproductive health through the development of new procedures, assays, digital apps, devices or technologies that improve the specificity, accuracy and rapidity of diagnosis and enhance the individualization, safety and convenience of clinical care.

## Questions people ask

### Is RFA-HD-22-010 still open?

No. It closed on July 29, 2021.

### Who can apply for Technologies to Advance Precision Medicine for Reproductive Health and Infertility (R43, R44 Clinical Trial Optional)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Technologies to Advance Precision Medicine for Reproductive Health and Infertility (R43, R44 Clinical Trial Optional)?

Closed July 29, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $1.5 million in total.

### Who has been funded under RFA-HD-22-010?

NIH RePORTER lists 2 projects funded under RFA-HD-22-010 in fiscal 2022, at 2 institutions. The most were at Optiva Fertility, Inc., Inherent Biosciences, Inc.

### Who has won Child Health and Human Development Extramural Research grants before?

The largest recipients over five fiscal years were Regents of the University of Michigan, The Johns Hopkins University, University of Washington. The program made 6,026 awards worth $6.0 billion in that time.